Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
28/08/2025 13:22
Galmed Pharmaceuticals Ltd GLMD.OQ reported a quarterly adjusted loss of 63 cents per share for the quarter ended June 30. The lone analyst forecast for the quarter was for a loss of 83 cents per share. Reported revenue was zero; analysts expected zero. Galmed Pharmaceuticals Ltd's reported EPS for the quarter was a loss of 63 cents. The company reported a quarterly loss of $2.5 million. Galmed Pharmaceuticals Ltd shares had fallen by 24.5% this quarter and lost 56.4% so far this year. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." This summary was machine generated from LSEG data August 28 at 12:22 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.83 | -0.63 | Beat |
| Mar. 31 2025 | -0.89 | -0.62 | Beat |